ICER draft evidence report on biologic treatments for asthma
The USA’s Institute for Clinical and Economic Review (ICER) has released a Draft Evidence Report assessing the clinical effectiveness and value of biologic treatments for asthma associated with Type 2 inflammation and/or allergic asthma. The draft report will be open to public comment until October 22, 2018.
The ICER’s report assesses the effectiveness and value of dupilumab (Dupixent, from Sanofi [Euronext: SAN] and Regeneron [Nasdaq: REGN]), omalizumab (Xolair, from Genentech and Novartis [NOVN: VX]), mepolizumab (Nucala, from GlaxoSmithKline [LSE: GSK]), reslizumab (Cinqair, from Teva Pharmaceutical Industries [NYSE: TEVA]), and benralizumab (Fasenra, from AstraZeneca [LSE: AZN]).
The ICER previously reviewed mepolizumab for its use in severe eosinophilic asthma and dupilumab for its use in atopic dermatitis. Dupilumab is currently under Food and Drug Administration review for use as add-on maintenance treatment in moderate-to-severe asthma, with an approval decision expected in October of 2018.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze